Key Findings of AURA 2019and action on AMR and AUDr Kathryn DavesonClinical Director, AURA

• Established in 2014 by the Australian Commission on Safety and Quality in Health Care 

• Funded by the Australian Government Department of Health and the states and territories. 

• Collates data voluntarily provided from states, territories, hospital and community settings

• Provides a comprehensive national and regional picture of AU and AMR to support Australia’s strategic response to AMR 

Antimicrobial Use and Resistance in Australia (AURA) Surveillance System

The AURA SurveillanceSystem

APAS

*The darker blue represents existing participating laboratories*The light blue represents laboratories that may participate in the future

Antimicrobial Usage

Hospital Use: Quantity

Hospital Use: Notable Changes

Hospital Use: Quality

Improving diagnosis

Adherence to guidelines

Improving appropriateness

Hospital Use: Quality

Community Use: Quantity

Community Use: Quality

Community Use: Quality

Guidelines concordance

Guidelines concordance

Reduced prescribing

Antimicrobial Resistance

Resistance: Escherichia coli

Resistance: Klebsiella pneumoniae

ESBL phenotype: States and territories

Resistance: Enterococcus faecium

Resistance:Neisseria gonorrhoeae

Resistance: Neisseria meningitidis

Resistance:Staphylococcusaureus (all)

MRSA: states and territories

Resistance: MRSA by remoteness

Carbapenemase producing Enterobacterales

Salmonella and Shigella

International Comparisons

Blood Cultures:

• Larger picture than ever before

• Strategic linkages of data to cohesive action can lead to large gains

• Prescribing improvements but more needed to contain progressive resistance

• Diversity of resistance and use by setting/remoteness provides opportunities for learning but also improvement

AURA 2019

AURA 2019 – next steps• Intensify efforts to reduce unnecessary prescribing in the

community and hospitals: amoxicillin-clavulanic acid and cefalexin

• Increased focus on respiratory prescribing including COPD

• Additional CARs to be added in 2019

• Expand representativeness for surveillance

• Laboratory collaboration: susceptibility testing and molecular capacity

• Improved end user utility to ensure continued value to clinicians, health service managers and policy makers.

Safetyandquality.gov.au

Twitter.com/ACSQHS

Youtube.com/user/ACSQHC